Medline raises roughly $6.3 billion, completes 2025’s largest U.S. IPO

Medline Industries Inc. priced its U.S. initial public offering at $29 a share and raised roughly $6.26 to $6.3 billion, completing the biggest American listing of 2025. The offering was upsized from earlier guidance and reflects strong demand for a company that supplies clinical products used across U.S. hospitals and health systems.

The deal comes nearly four years after a 2021 leveraged buyout valued at about $34 billion led by Blackstone, Carlyle and Hellman and Friedman. That buyout funded a push into global expansion and investment in distribution and logistics. Pre IPO materials indicated the company was targeting a valuation near $55 billion, and the final pricing positions Medline as one of the most valuable entrants into public markets this year.

Medline’s S1 filing had earlier contemplated an offering of 179 million shares with a proposed range of $26 to $30 per share. At the earlier top of range that would have implied roughly $5.37 billion in proceeds. The final price and larger gross proceeds reflect an upsized transaction and stronger investor demand than that initial guidance indicated.

The company is a major developer and distributor of medical supplies, selling products from surgical gowns and exam gloves to anesthesia kits and wheelchairs. An S1 disclosure highlighted investments in distribution that enable next day delivery to roughly 95 percent of the U.S. population. Medline also reported revenue growth since the 2021 buyout of roughly $5 billion, a metric the company used to argue for the scale and resilience of its business.

For private equity owners, the IPO represents a partial exit and a rare large scale liquidity event in a year when few offerings reached the same size. The listing roughly matches and surpasses other major transactions this year, placing it above prior large listings such as a $5.26 billion deal by a Chinese battery maker earlier in 2025. The proceeds will likely allow original investors to monetize a portion of their holdings while retaining ownership for future value creation.

Market participants will watch how Medline’s public valuation shapes investor expectations for other healthcare providers and industrial distributors. The deal underscores continued investor appetite for companies with predictable revenue streams, scale and logistics advantages, especially those serving hospitals where supply continuity mattered during past shocks.

Policy makers and hospital procurement directors may take particular interest in the public scrutiny that comes with listing. A public Medline will face greater pressure for transparency on pricing, contracting and supply chain resilience, questions that bear on health care costs and emergency preparedness. The company’s near nation wide delivery claim and recent investments in distribution mean its capital allocation choices in logistics will be visible to public investors and regulators.

Long term, the IPO highlights a trend of large private equity backed firms using public markets to crystallize gains after multibillion dollar buyouts. For hospitals and health systems, the listing could mean more disciplined capital investment in distribution from a major supplier, but it also raises questions about market concentration and bargaining dynamics in a critical segment of U.S. medical supply chains. The transaction, priced December 16, 2025, will be closely watched as a barometer of investor appetite for scaled supply chain businesses and for future exits in health care related industries.